ADRIAN ADAMS - 10 Oct 2023 Form 4 Insider Report for ACELRX PHARMACEUTICALS INC (ACRX)

Role: Director
Signature: /s/ Martha Adler, Attorney-In-Fact
Issuer symbol: ACRX
Transactions as of: 10 Oct 2023
Net transactions value: $0
Form type: 4
Filing time: 13 Dec 2023, 16:19:46 UTC
Previous filing: 08 Jun 2023
Next filing: 10 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRX	Common Stock	Award	$0	+581	+5.5%	$0.000000	11,168	10 Oct 2023	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRX	Stock Option (Right to Buy)	Award	$0	+3,487		$0.000000	3,487	10 Oct 2023	Common Stock	3,487	$0.6840	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2	100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company.
F3	Effective on October 25, 2022, the issuer effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F4	100% of the option shares subject to the option shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company.